Skip to content

Long-term observation of IBD patients - a nationwide German IBD Registry "CEDUR"

Long-term observation of IBD patients - a nationwide German IBD Registry "CEDUR" - CEDUR

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00038141
Enrollment
10000
Registered
2025-10-16
Start date
2018-05-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease and Ulcerative Colitis and indeterminate Colitis K50-K51

Interventions

Group 1: Observational study in adult patients with IBD (Inflammatory Bowel Disease). Observation period: 10 years and more. Data collected includes quality of life (PROM-10, sIBDQ, Facit-F, bowel urg

Sponsors

ImmunoRegister gGmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to No maximum

Inclusion criteria

Inclusion criteria: Crohn's disease, Ulcerative Colitis or Indeterminate Colitis

Exclusion criteria

Exclusion criteria: Gastrointestinal disorders other than those mentioned above

Design outcomes

Primary

MeasureTime frame
Assessment and Improvement of quality of care for IBD patients Parameter: oCDAI (Crohn's disease activity index) oMayo Score / partial Mayo Score (Ulcerative Colitis) oSES-CD Score (Simple Endoscopic Score for Crohn's disease) osIBDQ (short Inflammatory Bowel Disease Quality of Life) oBowel urgency scale (Lilly) oFACIT-F (Functional Assessment of Chronic Illness Therapy - Fatigue) oPROMIS-10 (Patient Related Outcome Measure Information System -10-item) Visit frequency according to clinical practice (approx. every 3 months)

Secondary

MeasureTime frame
• Long-term effectiveness of treatment with IBD therapies, e.g. drug persistence, effectiveness/side effects of treatment (-combinations), level of disease activity achieved • Assessment of incidence and prevalence of IBD • Real life Treatment costs / Pharmacoeconomic costs

Countries

Germany

Contacts

Public ContactStefanie Howaldt

ImmunoRegister gGmbH

Howaldt@immunoregister.de+4940423265150

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026